Theseus Pharmaceuticals Inc (THRX) Stock
THRX is no longer traded. Theseus Pharmaceuticals was delisted from the Nasdaq in February 2024.
Prices on this page are historical; the last trade was February 12, 2024 at $4.06.
Theseus Pharmaceuticals stock price history
THRX final trading statistics
- Final close
- $4.06
- Final trading day
- Feb 12, 2024
- Market cap at delisting
- $181.28M
- Shares outstanding
- 44.65M
- Final 52-week range
- $2.05 – $12.37
- Avg. volume (final 3 mo.)
- 849,662
- All-time high (split-adj.)
- $20.09 · Nov 2021
- All-time low (split-adj.)
- $2.12 · Nov 2023
- Return since IPO
- -60.7%
- Beta
- 3.98
- Book value / share
- $5.17
- Price / book
- 0.79
Theseus Pharmaceuticals annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2023 | $0.00 | -$56.6M | — |
| FY2022 | $0.00 | -$47.1M | -$1.30 |
| FY2021 | $0.00 | -$27.3M | -$14.01 |
| FY2020 | $0.00 | -$12.0M | -$11.43 |
| FY2019 | $0.00 | -$7.2M | -$6.97 |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Theseus Pharmaceuticals Inc
Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors. The company also develops THE-349, a fourth-generation selective epidermal growth factor receptor inhibitor to address C797X-mediated resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer. Its development programs address drug resistance mutations in key driver oncogenes, which are mutated genes that cause cancer. The company was incorporated in 2017 and is based in Cambridge, Massachusetts. As of February 14, 2024, Theseus Pharmaceuticals, Inc. operates as a subsidiary of Concentra Biosciences, LLC.
Theseus Pharmaceuticals stock FAQ
What happened to Theseus Pharmaceuticals stock?
Theseus Pharmaceuticals stock was delisted from the Nasdaq. Its final close was $4.06 on February 12, 2024.
Is THRX stock still trading?
No. THRX was delisted from the Nasdaq in February 2024 and no longer trades on a U.S. exchange.
What was the last price of THRX stock?
THRX closed at $4.06 on its final trading day, February 12, 2024, for a market value of about $181.28M.
What were Theseus Pharmaceuticals's revenue and earnings in its last full fiscal year?
Theseus Pharmaceuticals reported revenue of $0.00 and net income of -$56.6M in fiscal 2023, its last full year as a public company.
When did Theseus Pharmaceuticals go public?
Theseus Pharmaceuticals Inc stock began trading on October 7, 2021.